VALN
Valneva SE is a specialty vaccine company developing prophylactic vaccines across multiple modalities including inactivated, live-attenuated, and bioconjugate vaccines for infectious diseases. The company commercializes three travel vaccines (IXIARO, DUKORAL, and IXCHIQ) and maintains a clinical pipeline highlighted by VLA15, a Phase 3 Lyme disease vaccine candidate in partnership with Pfizer currently executing the VALOR efficacy trial, alongside Shigella4V2 (S4V2), a Phase 2 tetravalent bioconjugate vaccine candidate for shigellosis developed with LimmaTech that received FDA Fast Track designation in October 2024, and VLA1601, a Phase 1 inactivated Zika vaccine candidate. Revenue from its commercial travel vaccine business funds continued advancement of its development pipeline targeting high unmet need infectious diseases